<DOC>
	<DOCNO>NCT01398410</DOCNO>
	<brief_summary>The primary objective study examine long-term safety rabeprazole 5 mg 10 mg tablet administer daily participant confirm recurrence gastric duodenal ulcer endoscopic examination end 24 week treatment E3810-J081-308 ( NCI01397448 ) [ Double-Blind Phase ] study . From total 420 participant complete E3810-J081-308 study , 328 enter E3810-J081-309 ( NCT01398410 ) study .</brief_summary>
	<brief_title>Long-term Prevention Recurrent Gastric Duodenal Ulcers Caused Low-dose Aspirin With Rabeprazole ( E3810 ) Treatment ( Planetarium Study )</brief_title>
	<detailed_description>The E3810-J081-309 consist two arm : long-term rabeprazole group ( participant rabeprazole 5 10 mg arm E3810-J081-308 study enter rabeprazole 5 mg 10 mg arm E3810-J081-309 study ) newly-initiated rabeprazole group ( participant teprenone 150 mg arm E3810-J081-308 study enter rabeprazole 5 mg 10 mg arm E3810-J081-309 study ) .</detailed_description>
	<mesh_term>Ulcer</mesh_term>
	<mesh_term>Duodenal Ulcer</mesh_term>
	<mesh_term>Stomach Ulcer</mesh_term>
	<mesh_term>Aspirin</mesh_term>
	<mesh_term>Rabeprazole</mesh_term>
	<criteria>Inclusion Criteria Confirmed recurrence gastric duodenal ulcer endoscopy end 24 week treatment study E3810J081308 . Need continue receive lowdose aspirin ( 81 mg/day 100 mg/day ) study . Exclusion Criteria Confirmed recurrence gastric duodenal ulcer end 24 week treatment study E3810J081308 ( start trial ) thus withdraw trial .</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2015</verification_date>
	<keyword>Rabeprazole</keyword>
	<keyword>proton pump inhibitor</keyword>
	<keyword>Acetylsalicylic Acid</keyword>
	<keyword>Aspirin</keyword>
	<keyword>Gastric Ulcer</keyword>
	<keyword>Duodenal Ulcer</keyword>
</DOC>